Sagittal Balance and Health-Related Quality of Life Three Decades After in Situ Arthrodesis for High-Grade Isthmic Spondylolisthesis

2018 ◽  
Vol 100 (16) ◽  
pp. 1357-1365 ◽  
Author(s):  
Anders Joelson ◽  
Barbro I. Danielson ◽  
Rune Hedlund ◽  
Per Wretenberg ◽  
Karin Frennered
Keyword(s):  
Quality Of Life ◽  
Sagittal Balance ◽  
High Grade ◽  
Isthmic Spondylolisthesis ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related

Self-Image and Health-Related Quality of Life Three Decades After Fusion In Situ for High-Grade Isthmic Spondylolisthesis

2019 ◽  
Vol 7 (2) ◽  
pp. 293-297
Author(s):  
Anders Joelson ◽  
Elias Diarbakerli ◽  
Paul Gerdhem ◽  
Rune Hedlund ◽  
Per Wretenberg ◽  
...  
Keyword(s):  
Quality Of Life ◽  
High Grade ◽  
Isthmic Spondylolisthesis ◽  
Health Related Quality ◽  
Self Image ◽  
Related Quality ◽  
Health Related

scholarly journals Health-related quality of life and distress in elderly vs. younger patients with high-grade glioma—results of a multicenter study

2020 ◽  
Vol 28 (11) ◽  
pp. 5165-5175 ◽  
Author(s):  
Mirjam Renovanz ◽  
Anne-Katrin Hickmann ◽  
Minou Nadji-Ohl ◽  
Naureen Keric ◽  
Elke Weimann ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Elderly Patients ◽  
High Grade Glioma ◽  
High Grade ◽  
Health Related Quality ◽  
Younger Patients ◽  
Patient Reported ◽  
Related Quality ◽  
Health Related

Abstract Objective Half of all newly diagnosed patients with glioblastoma are > 65 years still with a poor prognosis. Preserving quality of life is of high importance. However, patient reported outcome (PRO) data in this patient group is rare. The aim was to compare health-related quality of life (HRQoL) and distress between elderly and younger patients with high-grade glioma (HGG). Methods We used baseline data of a prospective study where HGG patients were enrolled from 4 hospitals. Distress was measured using the distress thermometer (DT), HRQoL using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Core Questionnaire (QLQ-C30) plus brain module (BN20). We compared distress and HRQoL by age (≥ 65 vs. < 65 years), gender, performance score, and time since diagnosis using multivariate linear and logistic regressions. Results A total of n = 93 (30%) out of n = 309 patients were ≥ 65 years (mean 70 years, range 65–86 years). Mean DT score of elderly patients (5.2, SD 2.6) was comparable with younger patients (4.9, SD 2.6). Elderly patients reported significantly lower global health (GHS, mean elderly vs. younger; 50.8 vs. 60.5, p = 0.003), worse physical (56.8 vs. 73.3, p < 0.001) and lower cognitive functioning (51.1 vs. 63.2, p = 0.002), worse fatigue (52.5 vs. 43.5, p = 0.042), and worse motor dysfunction (34.9 vs. 23.6, p = 0.030). KPS and not age was consistently associated with HRQoL. Conclusion Physical functioning was significantly reduced in the elderly compared with younger HGG patients, and at the same time, emotional functioning and DT scores were comparable. KPS shows a greater association with HRQoL than with calendric age in HGG patients reflecting the particular importance for adequate assessment of HRQoL and general condition in elderly patients.

scholarly journals Health-related quality of life in patients with high-grade glioma

2009 ◽  
Vol 11 (1) ◽  
pp. 41-50 ◽  
Author(s):  
Jin-xiang Cheng ◽  
Xiang Zhang ◽  
Bo-Lin Liu
Keyword(s):  
Quality Of Life ◽  
High Grade Glioma ◽  
High Grade ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related

scholarly journals Assessment of clinical and nonclinical characteristics associated with health-related quality of life in patients with high-grade gliomas: a feasibility study

2014 ◽  
Vol 22 (5) ◽  
pp. 1349-1362 ◽  
Author(s):  
Kimberly R. Porter ◽  
Usha Menon ◽  
Nicholas A. Vick ◽  
John L. Villano ◽  
Michael L. Berbaum ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Feasibility Study ◽  
High Grade ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related ◽  
High Grade Gliomas

EPR19-071: Risk of Hematologic Toxicities and Health-Related Quality of Life Events in Patients With Hematologic Malignancies Treated With Ibrutinib: A Combined Analysis of 6 Phase III Trials

2019 ◽  
Vol 17 (3.5) ◽  
pp. EPR19-071
Author(s):  
Miguel Quirch ◽  
Sriman Swarup ◽  
Anita Sultan ◽  
Wai L. Thein ◽  
Zayar M. Oo ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Adverse Effects ◽  
Hematologic Malignancies ◽  
Lymphocytic Leukemia ◽  
Phase Iii ◽  
High Grade ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related

Background: Bruton’s tyrosine kinase (BTK) is essential for signaling of B-cell and chemokine receptors. Ibrutinib targets BTK and has become frontier in many hematologic malignancies. We undertook systematic review and pooled analysis of randomized controlled trials (RCTs) to determine the risk of hematologic toxicities and health-related quality of life (HRQOL) events associated with ibrutinib. Methods: We performed a comprehensive literature search using MEDLINE, EMBASE databases, and meeting abstracts through September 2018. Phase III RCTs that mention hematologic toxicities and HRQOL events as adverse effects were incorporated in the analysis. Mantel-Haenszel method was used to calculate the estimated pooled risk ratio with 95% CI. Random effects model was applied. Results: 6 phase III RCTs with a total of 1,811 patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, mantle-cell lymphoma, and Waldenstrom’s macroglobulinemia were eligible. Studies compared Ibrutinib (I) vs ofatumumab, I vs chlorambucil, I+ bendamustine (B) + rituximab (R) vs placebo + B+ R, I vs temsirolimus and I vs R were included in the analysis. The relative risks (RR) of all-grade side effects were as follows: anemia, 0.812 (95% CI: 0.565–1.168; P=.261); neutropenia, 0.956 (95% CI: 0.720–1.268; P=.754); thrombocytopenia, 1.054 (95% CI: 0.450–2.470; P=.904); fatigue, 0.896 (95% CI: 0.761–1.056; P=.192); pyrexia, 1.123 (95% CI: 0.893–1.413; P=.322); and arthralgia, 1.863 (95% CI: 1.101–3.152; P=.020). The RR of high-grade adverse effects were as follows: anemia, 0.522 (95% CI: 0.371–0.733; P<.0001); neutropenia, 0.969 (95% CI: 0.751–1.249; P=.807); thrombocytopenia, 0.608 (95% CI: 0.252–1.470; P=.270); fatigue, 0.618 (95% CI: 0.396–0.964; P=.034); pyrexia, 1.165 (95% CI: 0.534–2.542; P=.701); and arthralgia, 3.623 (95% CI: 0.743–17.663; P=.111). Conclusion: Ibrutinib increased the risk of all-grade arthralgia whereas the risks of high-grade anemia and fatigue were significantly lower in the study arm, favoring ibrutinib.

scholarly journals Health-related quality of life of long-term high-grade glioma survivors

2009 ◽  
Vol 11 (1) ◽  
pp. 51-58 ◽  
Author(s):  
Ingeborg Bosma ◽  
Jaap C. Reijneveld ◽  
Linda Douw ◽  
Maaike J. Vos ◽  
Tjeerd J. Postma ◽  
...  
Keyword(s):  
Quality Of Life ◽  
High Grade Glioma ◽  
High Grade ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related
Sign in / Sign up

Export Citation Format

Share Document